NSAIDs are among the most used drugs in the world. It is estimated that 30 million people take NSAIDs daily world-wide, without including drugs sold over the counter. They are effective in alleviating pain and inflammation. Even though they are very common there does not appear to be any clear-cut guidelines to when which NSAID should be used. It has therefore been the purpose of this thesis to analyze if there is a need to differentiate between different NSAIDs according to contemporary evidence. Since the withdrawal of rofecoxib in 2004 there has been a general idea that coxibs as a group are cardiotoxic, recent evidence suggests that this holds true for all NSAIDs however. As such this work included 5 drugs, three common over the counter non-selective NSAIDs; naproxen, ibuprofen and diclofenac as well as the two coxibs currently on the Swedish market; celecoxib and etoricoxib. Pubmed and google scholar were searched for relevant studies on the subject. The results showed that there is a need to differentiate between NSAIDs, however the clinical setting is complex and a one-size fits all solution is difficult to come by. Naproxen and moderate doses of celecoxib (100 mg b.i.d.) show the best cardiovascular profiles whilst etoricoxib, celecoxib and diclofenac show the best gastrointestinal profiles. Coxibs show similar upper GI-profiles as tNSAIDs if combined with PPI however PPI are not without adverse events and the lower GI is not affected by PPI. Longer half-life is in general the better option in situations with lasting pain since it has been shown that lower dosing intervals increase adherence. In terms of pain management there does not appear to be any differences in efficacy amongst different NSAIDs

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal